Premium
Early weight changes after birth and serum high‐molecular‐weight adiponectin level in preterm infants
Author(s) -
Yoshida Tomohide,
Nagasaki Hiraku,
Asato Yoshihide,
Ohta Takao
Publication year - 2011
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/j.1442-200x.2011.03420.x
Subject(s) - medicine , birth weight , anthropometry , gestational age , low birth weight , adiponectin , obstetrics , gestation , pediatrics , physiology , obesity , pregnancy , biology , insulin resistance , genetics
Background: Extra‐uterine growth retardation (EUGR) is associated with an increased risk for cardiometabolic diseases later in life. The aim of the present study was to examine the relationship between early weight change after birth in preterm infants and adiponectin (adn) multimeric complexes. Methods: Subjects included 28 preterm infants born between weeks 24 and 33 of gestation. Serum adn multimeric complexes and the anthropometric parameters were measured in preterm infants at birth and at corrected term. Results: Bodyweight (BW) decreased during the first week of life, with birthweight restored at approximately 19 days after birth. Nineteen of the subjects had EUGR at corrected term. Total (T)‐adn, high‐molecular‐weight (H)‐adn, and the ratio of H‐adn to T‐adn (H/T‐adn) were significantly elevated at corrected term than at birth. Postmenstrual age, birthweight, birth length and lowest BW after birth were positively correlated with H‐adn and H/T‐adn. Weight reduction after birth was negatively correlated with H‐adn. Age to restore birthweight was negatively correlated with T‐adn, H‐adn and H/T‐adn. Stepwise multiple regression analysis indicated age to restore birthweight as the major predictor of T‐adn and H‐adn. Discussion: Early weight changes after birth may alter serum adn level in preterm infants at corrected term. The appropriate nutritional support in the early postnatal period could reduce the prevalence of EUGR and the future risk for cardiometabolic diseases.